HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Chen, M.-C. Articles by Chai, H.-T. Search for Related Content PubMed PubMed Citation Articles by Chen, M.-C. Articles by Chai, H.-T.

Mechanism of Reducing Platelet Activity by Percutaneous Transluminal Mitral Valvuloplasty in Patients With Rheumatic Mitral Stenosis^*

^* From the Department of Internal Medicine (Drs. M.-C. Chen, Wu, Yip, Y.-H. Chen, Cheng, and Chai), Division of Cardiology, Chang Gung Memorial Hospital, Kaohsiung; and the Department of Biological Sciences (Dr. Chang), National Sun Yat-Sen University, Kaohsiung, Taiwan, ROC.

Correspondence to: Mien-Cheng Chen, MD, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, 123, Ta Pei Rd, Niao Sung Hsiang, Kaohsiung Hsien 83301, Taiwan, ROC; e-mail: chenmien{at}ms76.hinet.net

Background: Previous studies have demonstrated that platelet activity significantly decreased after optimal percutaneous transluminal mitral valvuloplasty (PTMV) in patients with rheumatic mitral stenosis (MS). However, the mechanism of reducing platelet activity by valvuloplasty remains unclear.

Methods and results: We studied 19 patients with symptomatic MS who were undergoing PTMV. The fractions of unstimulated platelets expressing P-selectin in the venous blood obtained before, and at the 1-week and 4-week follow-ups after PTMV were determined by flow cytometry. The mitral valve areas, measured before and at the 1-week follow-up after PTMV, were calculated by means of the Doppler pressure half-time method. The mean (± SD) area of the mitral valve increased significantly after PTMV (1.05 ± 0.17 vs 1.44 ± 0.27 cm², respectively; p < 0.0001). The mean left atrial area was reduced in size significantly after PTMV (36.6 ± 11.4 vs 33.9 ± 13.4 cm², respectively; p < 0.05). The mean left atrial pressure (23.3 ± 5.1 vs 18.0 ± 5.8 mm Hg, respectively; p < 0.0001) and the mean pulmonary arterial pressure (31.4 ± 7.8 vs 26.1 ± 7.7 mm Hg, respectively; p < 0.0001) fell significantly after PTMV. The fraction of platelets expressing P-selectin in the venous blood fell significantly after PTMV (before PTMV, 4.7 ± 2.4%; 1 week after PTMV, 2.2 ± 2.1%; 4 weeks after PTMV, 2.0 ± 1.7%; p < 0.0001). Correlation analysis demonstrated that there was a significantly direct relationship between the magnitude of increase in mitral valve area and the magnitude of decrease in the fraction of platelets expressing P-selectin in the venous blood 4 weeks after PTMV (p = 0.0013; r = 0.682). However, there was no significant correlation between the magnitude of decrease in the fraction of platelets expressing P-selectin in the venous blood and the magnitude of decrease in the left atrial area, the decrease in left atrial pressure, or the decrease in the pulmonary artery pressure after PTMV.

Conclusions: In patients with moderate-to-severe MS, increased platelet activation fell significantly after PTMV. It was the increase in mitral valve area by PTMV, instead of hemodynamic and echocardiographic factors, that accounted for the decrease in the fraction of venous platelets expressing P-selectin after PTMV.

Key Words: mitral stenosis • platelet • valvuloplasty

This article has been cited by other articles:

				C. A. Dezsi, A. Szucs, G. Szucs, A. Roka, O. Kiss, D. Becker, and B. Merkely Short-term effect of rate control on plasma endothelin levels of patients with tachyarrhythmias. Experimental Biology and Medicine, June 1, 2006; 231(6): 852 - 856. [Abstract] [Full Text] [PDF]

				B. A. Carabello Modern Management of Mitral Stenosis Circulation, July 19, 2005; 112(3): 432 - 437. [Full Text] [PDF]

				M.-C. Chen, H.-W. Chang, C.-J. Wu, C.-H. Yang, W. C. Hung, K.-H. Yeh, and M. Fu Percutaneous Transluminal Mitral Valvuloplasty Reduces Circulating Soluble CD40 Ligand in Rheumatic Mitral Stenosis Chest, July 1, 2005; 128(1): 36 - 41. [Abstract] [Full Text] [PDF]

				D. S. G. Conway, G. Y. H. Lip, M.-C. Chen, T. Hirai, K. Sakurai, and H. Inoue Further Insights Into the Prothrombotic State in Mitral Stenosis and Atrial Flutter Chest, June 1, 2004; 125(6): 2361 - 2363. [Full Text] [PDF]